310 related articles for article (PubMed ID: 26811623)
21. Comparison of intrahepatic and pancreatic perfusion on fusion images using a combined SPECT/CT system and assessment of efficacy of combined continuous arterial infusion and systemic chemotherapy in advanced pancreatic carcinoma.
Ikeda O; Tamura Y; Nakasone Y; Shiraishi S; Kawanaka K; Tomiguchi S; Yamashita Y; Takamori H; Kanemitsu K; Baba H
Cardiovasc Intervent Radiol; 2007; 30(5):912-21. PubMed ID: 17710478
[TBL] [Abstract][Full Text] [Related]
22. Feasibility of pre-operative chemoradiotherapy with gemcitabine to treat pancreatic cancer in patients with impaired renal function.
Tomimaru Y; Eguchi H; Satoh T; Tomokuni A; Asaoka T; Wada H; Marubashi S; Ogawa K; Takehara T; Mori M; Doki Y; Nagano H
Jpn J Clin Oncol; 2015 Apr; 45(4):343-8. PubMed ID: 25589454
[TBL] [Abstract][Full Text] [Related]
23. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
24. Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients.
Oziel-Taieb S; Faure M; Gilabert M; Autret A; Turrini O; Moureau-Zabotto L; Giovannini M; Rousseau F; Raoul JL
J Gastrointest Cancer; 2016 Mar; 47(1):15-9. PubMed ID: 26545612
[TBL] [Abstract][Full Text] [Related]
25. Pancreaticoduodenectomy of pancreatic ductal adenocarcinoma in the elderly.
Kang CM; Kim JY; Choi GH; Kim KS; Choi JS; Lee WJ; Kim BR
Yonsei Med J; 2007 Jun; 48(3):488-94. PubMed ID: 17594158
[TBL] [Abstract][Full Text] [Related]
26. Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma.
Swords DS; Mulvihill SJ; Firpo MA; Scaife CL
JAMA Oncol; 2018 Aug; 4(8):1129-1130. PubMed ID: 30003235
[TBL] [Abstract][Full Text] [Related]
27. Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma.
Cloyd JM; Wang H; Egger ME; Tzeng CD; Prakash LR; Maitra A; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Overman MJ; Koay EJ; Das P; Herman JM; Kim MP; Vauthey JN; Aloia TA; Fleming JB; Lee JE; Katz MHG
JAMA Surg; 2017 Nov; 152(11):1048-1056. PubMed ID: 28700784
[TBL] [Abstract][Full Text] [Related]
28. Perioperative outcomes and survival in elderly patients undergoing laparoscopic distal pancreatectomy.
Sahakyan MA; Edwin B; Kazaryan AM; Barkhatov L; Buanes T; Ignjatovic D; Labori KJ; Røsok BI
J Hepatobiliary Pancreat Sci; 2017 Jan; 24(1):42-48. PubMed ID: 27794204
[TBL] [Abstract][Full Text] [Related]
29. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma.
Alemi F; Alseidi A; Scott Helton W; Rocha FG
Curr Probl Surg; 2015 Sep; 52(9):362-98. PubMed ID: 26363649
[No Abstract] [Full Text] [Related]
30. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.
Nordby T; Hugenschmidt H; Fagerland MW; Ikdahl T; Buanes T; Labori KJ
Eur J Surg Oncol; 2013 Jun; 39(6):559-66. PubMed ID: 23498362
[TBL] [Abstract][Full Text] [Related]
31. Pancreatic ductal adenocarcinoma: biological hallmarks, current status, and future perspectives of combined modality treatment approaches.
Orth M; Metzger P; Gerum S; Mayerle J; Schneider G; Belka C; Schnurr M; Lauber K
Radiat Oncol; 2019 Aug; 14(1):141. PubMed ID: 31395068
[TBL] [Abstract][Full Text] [Related]
32. Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis.
Rangarajan K; Pucher PH; Armstrong T; Bateman A; Hamady Z
Ann R Coll Surg Engl; 2019 Sep; 101(7):453-462. PubMed ID: 31304767
[TBL] [Abstract][Full Text] [Related]
33. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection.
Ren W; Xourafas D; Ashley SW; Clancy TE
J Surg Res; 2021 Jan; 257():605-615. PubMed ID: 32947122
[TBL] [Abstract][Full Text] [Related]
34. Irreversible electroporation: a novel therapy for stage III pancreatic cancer.
Weiss MJ; Wolfgang CL
Adv Surg; 2014; 48():253-8. PubMed ID: 25293620
[No Abstract] [Full Text] [Related]
35. Neo-adjuvant therapy for pancreatic cancer: hope for the future.
Borazanci E; Sckolnik S; Amini A
Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):579-589. PubMed ID: 30979348
[TBL] [Abstract][Full Text] [Related]
36. Impact of completeness of adjuvant gemcitabine, relapse pattern, and subsequent therapy on outcome of patients with resected pancreatic ductal adenocarcinoma - A pooled analysis of CONKO-001, CONKO-005, and CONKO-006 trials.
Kurreck A; Weckwerth J; Modest DP; Striefler JK; Bahra M; Bischoff S; Pelzer U; Oettle H; Kruger S; Riess H; Sinn M
Eur J Cancer; 2021 Jun; 150():250-259. PubMed ID: 33940349
[TBL] [Abstract][Full Text] [Related]
37. Comparison of 4- and 4 plus-courses S-1 administration as adjuvant chemotherapy for pancreatic ductal adenocarcinoma.
Li B; Shen S; You S; Zhang G; Gao S; Shi X; Wang H; Yin X; Xu X; Guo S; Jin G
BMC Cancer; 2021 May; 21(1):612. PubMed ID: 34034684
[TBL] [Abstract][Full Text] [Related]
38. Predictive factors for long-term survival after surgery for pancreatic ductal adenocarcinoma: Making a case for standardized reporting of the resection margin using certified cancer center data.
Weyhe D; Obonyo D; Uslar VN; Stricker I; Tannapfel A
PLoS One; 2021; 16(3):e0248633. PubMed ID: 33735191
[TBL] [Abstract][Full Text] [Related]
39. Evolving treatment options for locally advanced unresectable pancreatic ductal adenocarcinoma.
Cinar P; Ko AH
J Natl Compr Canc Netw; 2014 Feb; 12(2):167-72. PubMed ID: 24586078
[TBL] [Abstract][Full Text] [Related]
40. A single institution experience of the treatment of pancreatic ductal carcinoma: The demand and the role of radiation therapy.
Kubo K; Wadasaki K; Komichi D; Sasaki T; Yamada H; Matsugu Y; Itamoto T; Doi M; Shinozaki K
PLoS One; 2019; 14(12):e0227305. PubMed ID: 31887205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
